BUSINESS● LOW1h ago · Sep 8, 2026, 7:51 AM
Pharma major plummets over 10% after third trial disappointment in a week
CNBC · global
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS26m agoNovartis drops 13% on trial failure, dragging Dyne and SareptaSeeking Alpha TechBUSINESS33m agoAderans subsidiary apologizes for 2019 stealth marketing, stating it was 'inappropriate'Asahi ShimbunBUSINESS43m agoMistral AI raises record €3 billion in Samsung-led funding roundEuroNews [en]BUSINESS44m agoHong Kong reserves right to seek compensation over faulty hospital lift workSouth China Morning Post